MX9307175A - Hemoglobina especificamente reticulada con funcionalidad libre. - Google Patents

Hemoglobina especificamente reticulada con funcionalidad libre.

Info

Publication number
MX9307175A
MX9307175A MX9307175A MX9307175A MX9307175A MX 9307175 A MX9307175 A MX 9307175A MX 9307175 A MX9307175 A MX 9307175A MX 9307175 A MX9307175 A MX 9307175A MX 9307175 A MX9307175 A MX 9307175A
Authority
MX
Mexico
Prior art keywords
reaction
crosslinking
hemoglobin
effects
reagent
Prior art date
Application number
MX9307175A
Other languages
English (en)
Inventor
Ronald Kluger
Yong Hong Song
Original Assignee
Ronald Kluger
Yong Hong Song
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ronald Kluger, Yong Hong Song filed Critical Ronald Kluger
Publication of MX9307175A publication Critical patent/MX9307175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

La hemoglobina se retícula específicamente en el sitio en su forma tetramérica, mediante su reacción con un reagente presuncional que combina efectos electrostáticos, efectos estéricos y la presencia de grupos funcionales, de tal manera que dos de los grupos funcionales reaccionan con sitios específicos sobre la hemoglobina, mientras que el tercer sitio se deja libre para reaccionar con compuestos nucleofílicos endógenos. Un ejemplo específico de este reagente reticulante es tris(3, 5-dibromosalicilato) de trimesoílo, TTDS, que efectúa la reticulación específica entre los grupos amino de lisina-82 sobre cada subunidad ß respectiva. Mientras que el reagente reticulante TTDS tiene tres grupos carboxilo disponibles para la reacción de reticulación, solamente dos reaccionan de esta manera, dejando un carboxilo libre para la reacción con los nucleófilos exógenos, por ejemplo, para hacer al producto de hemoglobina útil como un portador para compuestos nucleofílicos a través del sistema circulatorio del cuerpo.
MX9307175A 1992-11-18 1993-11-17 Hemoglobina especificamente reticulada con funcionalidad libre. MX9307175A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/978,418 US5399671A (en) 1992-11-18 1992-11-18 Specifically crosslinked hemoglobin with free functionality

Publications (1)

Publication Number Publication Date
MX9307175A true MX9307175A (es) 1994-08-31

Family

ID=25526077

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9307175A MX9307175A (es) 1992-11-18 1993-11-17 Hemoglobina especificamente reticulada con funcionalidad libre.

Country Status (15)

Country Link
US (1) US5399671A (es)
EP (1) EP0669940B1 (es)
JP (1) JPH08503456A (es)
AT (1) ATE176673T1 (es)
AU (1) AU683029B2 (es)
CA (1) CA2149132A1 (es)
CZ (1) CZ128695A3 (es)
DE (1) DE69323497T2 (es)
HU (1) HUT70740A (es)
MX (1) MX9307175A (es)
NZ (1) NZ257513A (es)
PL (1) PL309032A1 (es)
RU (1) RU95112535A (es)
SK (1) SK64195A3 (es)
WO (1) WO1994011399A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK145092D0 (es) * 1992-12-03 1992-12-03 Novo Nordisk As
AU668294B2 (en) * 1993-03-16 1996-04-26 Hemosol Inc. Selective crosslinking of hemoglobins by oxidized, ring-opened saccharides
DE69608406D1 (de) * 1995-06-16 2000-06-21 Ronald Kluger Multifunktionelle vernetzungsreagenzien für haemoglobin und vernetzte haemoglobinconjugate
US5917020A (en) * 1997-01-15 1999-06-29 Kluger; Ronald H. Bis-tetrameric hemoglobin and reagents for its production
CA2308277A1 (en) * 1997-11-03 1999-05-14 Ronald H. Kluger Hemoglobin with chemically introduced disulfide cross-links and preparation thereof
JP2001522863A (ja) * 1997-11-07 2001-11-20 コンジュケム，インコーポレーテッド Ｒｇｄ含有ペプチドおよび内因性担体の新規コンジュゲート
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
EP1660133B1 (en) * 2003-05-15 2018-04-18 Therapure Biopharma Inc. Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
US7875293B2 (en) * 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
WO2010011096A2 (en) 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8642744B2 (en) * 2010-10-28 2014-02-04 Agilent Technologies, Inc. Crosslinking reagent for analysis of protein-protein interaction
WO2017197499A1 (en) * 2016-04-25 2017-11-23 The Governing Council Of The University Of Toronto Stabilized hemoglobin-avidin assembly and method of preparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529719A (en) * 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4598064A (en) * 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
GB8710598D0 (en) * 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
US5250665A (en) * 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation

Also Published As

Publication number Publication date
CZ128695A3 (en) 1996-01-17
DE69323497D1 (de) 1999-03-25
RU95112535A (ru) 1997-03-20
JPH08503456A (ja) 1996-04-16
ATE176673T1 (de) 1999-02-15
NZ257513A (en) 1997-02-24
PL309032A1 (en) 1995-09-18
AU5415394A (en) 1994-06-08
SK64195A3 (en) 1995-09-13
WO1994011399A1 (en) 1994-05-26
AU683029B2 (en) 1997-10-30
HU9501448D0 (en) 1995-06-28
DE69323497T2 (de) 1999-09-16
US5399671A (en) 1995-03-21
HUT70740A (en) 1995-10-30
EP0669940B1 (en) 1999-02-10
EP0669940A1 (en) 1995-09-06
CA2149132A1 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
MX9307175A (es) Hemoglobina especificamente reticulada con funcionalidad libre.
DE3588219D1 (de) T-Zellenrezeptor, spezifisch für Antigenpolypeptide und verwandte Polynukleotide
ATE82525T1 (de) Kieseltraeger.
IL76412A0 (en) Carrier for immune assay
AU3075389A (en) Functionally specific antibodies
ES2176456T3 (es) Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.
SE8400085D0 (sv) Farmaceutisk komposition (ii)
AR241140A2 (es) Procedimiento para aislamiento de (oxi)hemoglobina de soluciones o mezclas a base de la misma"
TW273514B (es)
NO933520L (no) Fusjonsproteiner for promedikament-aktivering
AU3358378A (en) Polyamide carrier for fixing biologically active proteins
AU7657387A (en) Apoprotein b-100 specific monoclonal antibodies
ES517857A1 (es) Procedimiento para preparar nuevos derivados de aminosulfonil-urea.
SE8008096L (sv) Sett att binda ett protein till en berare innehallande hydroxylgrupper
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
ATE58306T1 (de) Chromatographische trennungsprozesse an polypeptidtraegermaterial.
ES2111757T3 (es) Regiones antigenicas de complejos de particulas liberadas por tumores (tlp) y anticuerpos contra los mismos.
ATE21257T1 (de) Verfahren zur herstellung von quaternaeren ammniumgruppen enthaltenden siliciumverbindungen, ihre reaktionsprodukte und deren anwendung.
FI884470A0 (fi) Biologiskt diagnostiskt analyseringssystem.
FI833654A (fi) Automatiskt styrsystem foer foerspaenningen i bildroer kompenserad foer olikheter i ledningsfoermaobildroerets elektronkanon
ATE26109T1 (de) Acetylcystein-salze, ihre herstellung und verwendung.
TR200001135T2 (tr) Dofetilid polimorfları.
FI941394A (fi) Peptidejä,jotka kykenevät säätelemään akrosomireaktiota
IE810185L (en) N-phenyl-n'-cyano-o-phenylisoureas
IT8223855V0 (it) Struttura di supporto per coppie di pulsanti, atta a consentire l'illuminazione congiunta degli stessi, mediante un'unica sorgente luminosa.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees